- Home
- CTOR vs ADAP Comparison
CTOR vs ADAP Comparison
Compare CTOR & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- ADAP
- Stock Information
- Founded
- CTOR 2021
- ADAP 2008
- Country
- CTOR United States
- ADAP United Kingdom
- Employees
- CTOR N/A
- ADAP N/A
- Industry
- CTOR
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- ADAP Health Care
- Exchange
- CTOR NYSE
- ADAP Nasdaq
- Market Cap
- CTOR 63.7M
- ADAP 75.5M
- IPO Year
- CTOR N/A
- ADAP 2015
- Fundamental
- Price
- CTOR $5.05
- ADAP $0.24
- Analyst Decision
- CTOR Buy
- ADAP Buy
- Analyst Count
- CTOR 2
- ADAP 6
- Target Price
- CTOR $6.00
- ADAP $1.35
- AVG Volume (30 Days)
- CTOR 3.1M
- ADAP 694.1K
- Earning Date
- CTOR 08-11-2025
- ADAP 08-11-2025
- Dividend Yield
- CTOR N/A
- ADAP N/A
- EPS Growth
- CTOR N/A
- ADAP N/A
- EPS
- CTOR N/A
- ADAP N/A
- Revenue
- CTOR N/A
- ADAP $179,639,000.00
- Revenue This Year
- CTOR N/A
- ADAP N/A
- Revenue Next Year
- CTOR N/A
- ADAP $35.48
- P/E Ratio
- CTOR N/A
- ADAP N/A
- Revenue Growth
- CTOR N/A
- ADAP 878.53
- 52 Week Low
- CTOR $0.55
- ADAP $0.20
- 52 Week High
- CTOR $49.00
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- ADAP 38.54
- Support Level
- CTOR N/A
- ADAP $0.24
- Resistance Level
- CTOR N/A
- ADAP $0.26
- Average True Range (ATR)
- CTOR 0.00
- ADAP 0.02
- MACD
- CTOR 0.00
- ADAP -0.00
- Stochastic Oscillator
- CTOR 0.00
- ADAP 15.25
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.